$25.58▴ 2.85%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
Not enough data yet
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
+6.2%year over year
Healthy
Revenue is growing at a steady pace.
Leverage
Lowdebt to assets
Healthy
A modest, well-covered debt load.
More coming: dilution / share-count creep.
Fair value
Undervalued
Trading about 34% below our fair-value range
A cash-flow (DCF) estimate cross-checked against peer multiples.
✦ The read
Pacira BioSciences, Inc.'s earnings-quality signal is not available yet. Revenue is growing at a steady pace. A modest, well-covered debt load.
Key numbers
Valuation
EPS (TTM)$0.35
TTM (trailing 12 months, through fiscal Q2 FY2026)
Profitability
Net margin2.0%
TTM (trailing 12 months, through fiscal Q2 FY2026)
Size
Revenue (TTM)$746.16M
TTM (trailing 12 months, through fiscal Q2 FY2026)
Recent news
Sentiment · last 30 days2 articles
1 bullish1 neutral0 bearish
Pacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026
Osteoarthritis Market Expected to Showcase Moderate Growth at a CAGR of 3% During the Forecast Period (2026–2036) Driven by Emerging Therapies and Rising Disease Burden | DelveInsight
Signals and key numbers are from the fiscal Q2 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.